Synjardy (empagliflozin recalls
The FDA has published 2 recalls involving Synjardy (empagliflozin since 2021. The latest was reported on 8 Jul 2026. Most were for manufacturing (cgmp) deviations. Boehringer Ingelheim Pharmaceuticals has the most recalls in this group. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls2since 2021
Last 12 months1reported
Class I00% of total
Ongoing1latest 8 Jul 2026
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 2 100%Class III 0 0%
Why synjardy (empagliflozin is recalled
Companies
By year
Ongoing synjardy (empagliflozin recalls
1 active| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Synjardy XR Tablets (empagliflozin recalled by Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals | Manufacturing (CGMP) Deviations | OH |
All synjardy (empagliflozin recalls, newest first
2 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Synjardy XR Tablets (empagliflozin recalled by Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals | Manufacturing (CGMP) Deviations | OH |
| Drug | CLASS II | Synjardy (empagliflozin and metformin hydrochloride) recalled | Cardinal Health | Manufacturing (CGMP) Deviations | FL, GA, SC |
Should you stop taking Synjardy (empagliflozin?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.